Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 1-2, 2008, Pages 177-184

  Raynaud, Jean Pierre ^a   Aumonier, Céline ^b   Gualano, Virginie ^b   Betea, Daniella ^c   Beckers, Albert ^c  

^a SORBONNE UNIVERSITÉ   (France)

^b CEPHAC Europe   (France)

^c Centre Hospitalier Universitaire   (Belgium)

Author keywords

Hormone therapy; Hypogonadism; Testosterone; Transdermal delivery system

Indexed keywords

FOLLITROPIN; TESTOPATCH; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG HALF LIFE; HEADACHE; HORMONAL THERAPY; HUMAN; HYPOGONADISM; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH;

ADHESIVENESS; ADHESIVES; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG TOLERANCE; HALF-LIFE; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; SAFETY; TESTOSTERONE;

EID: 40849145444     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.02.004     Document Type: Article

References (29)

1. Jeffcoate S.L., Brooks R.V., Lim N.Y., London D.R., Prunty F.T., and Spathis G.S. Androgen production in hypogonadal men. J. Endocrinol. 37 (1967) 401-411
2. Dobs A.S., Meikle A.W., Arver S., Sanders S.W., Caramelli K.E., and Mazer N.A. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 84 (1999) 3469-3478
3. Bain J. Male hypogonadism. Comp. Ther. 9 (1983) 17-24
4. Meikle A.W., Mazer N.A., Moellmer J.F., Stringham J.D., Tolman K.G., Sanders S.W., and Odell W.D. Enhanced transdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol. Metab. 74 (1992) 623-628
5. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P., Cunningham G., and Matsumoto A. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metabol. 85 (2000) 2839-2853
6. Johnsen S.G., Benett E.P., and Jensen V.G. Therapeutic effectiveness of oral testosterone. Lancet 2 (1974) 1473-1475
7. Ross R.J., Jabbar A., Jones T., Roberts B., Dunkley K., Hall J., Long A., Levine H., and Cullen D. Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur. J. Endocrinol. 150 (2004) 57-63
8. Stuenkel C.A., Dudley R.E., and Yen S.S. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex stimulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. Metabol. 72 (1991) 1054-1059
9. Matsumoto A.M. Hormonal therapy of male hypogonadism. Endocrinol. Metab. Clin. North Am. 23 (1994) 857-875
10. Handelsman D.J., Conway A.J., and Boyla L.M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. 71 (1990) 216-222
11. Korenman S.G., Viosca S., Garza D., Guralnik M., Place V., Campbell P., and Davis S.S. Androgen therapy of hypogonadal men with transcrotal testosterone systems. Am. L. Med. 83 (1987) 471-478
12. Wang C., Berman N., Longstreth J.A., Chuapoco B., Hull L., Steiner B., Faulkner S., Dudley R.E., and Swerdloff R.S. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J. Clin. Endocrinol. Metab. 85 (2000) 964-969
13. Swerdloff R.S., Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumoto A.M., Snyder P.J., Weber T., Longstreth J., and Berman N. Long-term Pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85 (2000) 4500-4510
14. Chik Z., Johnston A., Tucker A., Chew S.L., Mickaels L., and Alam C. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br. J. Clin. Pharmacol. 10 (2005) 1-5
15. Westaby D., Ogle S., Paradinas F., Randell J., and Murray-Lyon I. Liver damage from long-term methyltestosterone. Lancet 2 (1977) 262-273
16. Brocks D.R., Meikle A.W., Boike S.C., Mazer N.A., Zariffa N., Audet P.R., and Jorkasky D.K. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J. Clin. Pharmacol. 36 (1996) 732-739
17. In: Gibaldi M., Perrier D., and Dekker (Eds). Pharmacokinetics (2nd edition revised and expanded) vol. 15 (1982), Drugs and Pharmaceutical Sciences, New York
18. In: Rowland M., and Tozer T. (Eds). Clinical Pharmacokinetics-Concepts and Applications (3rd ed.) (1995), Lea & Febiger, Philadelphia/London
19. Food and drugs administration, FDA Center for drug evaluation and research, Guidance for industry. Skin irritation and sensitization testing of generic transdermal drug products, December
20. W.L. Thompson, L.R. Brunelle, G.G. Enas, P.J. Simpson, L. Randy, Delta-limits mber 1999, From «Routine Laboratory Tests in Clinical Trials» Walker Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana in «Clinical Trials and Tribulations» 1988.
21. Standardisation of definitions and criteria of causality assessment of adverse drug reactions: drugs-induced liver disorders, International consensus Meeting Report, Int. J Clin. Pharmacol., Ther. Toxicol 28 (1990) 317-322.
22. Standardisation of definitions and criteria of causality assessment of adverse drug reactions: drugs-induced cytopenia, Int. J. Clin. Pharmacol., Ther. Toxicol. 29 (1991) 75-81.
23. Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Rajaram L., and Mazer N.A. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 1832-1840
24. McClellan K.J., and Goa K.L. Transdermal testosterone. Drugs 55 (1998) 253-258
25. Mazer N., Bell D., Wu J., Fischer J., Cosgrove M., and Eliers B. Comparison of the steady state pharmacokinetics, metabolism and variability of a transdermal testosterone patch versus a transdermal gel in hypogonadal men. J. Sex Med. 2 (2005) 213-226
26. In: Meikle A.W., Arver S., Dobs A., Sanders S., Mazer N., and Bhasin S. (Eds). Androderm: A Permeation Enhanced Non-scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism, Pharmacology, Biology and Clinical Application of Androgens (1996), Wiley-Liss Inc.
27. Wilson D.E., Kaidbay K., Boike S.C., and Jorkasky D.K. Use of topical corticosterol pre-treatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal delivery. Clin. Ther. 20 (1998) 229-306
28. Yu Z., Gupta S.K., Hwang S.S., Cook D.M., Duckett M.J., and Atkinson L.E. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. J. Clin. Pharmacol. 37 (1997) 1129-1138
29. Yu Z., Gupta S.K., Hwang S.S., Kipnes M.S., Mooradian A.D., Snyder P.J., and Atkinson L.E. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J. Clin. Pharmacol. 37 (1997) 1139-1145